NASDAQ:CBAY - CymaBay Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.43
  • Forecasted Upside: 231.07 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 1 Strong Buy Ratings
$3.15
▲ +0.08 (2.61%)

This chart shows the closing price for CBAY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CymaBay Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CBAY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CBAY

Analyst Price Target is $10.43
▲ +231.07% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for CymaBay Therapeutics in the last 3 months. The average price target is $10.43, with a high forecast of $14.00 and a low forecast of $7.00. The average price target represents a 231.07% upside from the last price of $3.15.

This chart shows the closing price for CBAY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in CymaBay Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/26/2020
  • 1 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/24/2020
  • 1 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2021
  • 1 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2021
  • 1 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/21/2021
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/19/2021
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/18/2021
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/17/2022

Latest Recommendations

  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/11/2021Raymond JamesBoost Price TargetStrong-Buy$12.00 ➝ $14.00High
8/18/2021B. RileyLower Price TargetBuy$13.00 ➝ $10.00Medium
8/15/2021SVB LeerinkReiterated RatingBuy$10.00High
8/3/2021HC WainwrightLower Price TargetBuy$13.00 ➝ $12.00Low
6/21/2021JonestradingReiterated RatingBuy$8.00Medium
6/14/2021JonestradingInitiated CoverageBuy$8.00Medium
5/18/2021SVB LeerinkReiterated RatingBuy$10.00Medium
3/31/2021Cantor FitzgeraldLower Price TargetHold ➝ Overweight$20.00 ➝ $7.00Medium
3/9/2021Piper SandlerReiterated RatingBuy$12.00Low
11/30/2020Smith Barney CitigroupBoost Price Target$9.00 ➝ $10.00Low
11/6/2020Raymond JamesBoost Price TargetStrong-Buy$11.00 ➝ $12.00High
11/6/2020SVB LeerinkBoost Price TargetOutperform$8.00 ➝ $10.00High
10/9/2020Cantor FitzgeraldReiterated RatingOverweightMedium
9/29/2020Lifesci CapitalReiterated RatingOutperformMedium
9/10/2020OppenheimerReiterated RatingBuy$14.00Medium
9/9/2020B. RileyBoost Price Target$9.00 ➝ $13.00High
8/25/2020CitigroupBoost Price TargetBuy$7.00 ➝ $9.00Medium
8/12/2020B. RileyReiterated RatingBuy$9.00Low
8/11/2020Raymond JamesBoost Price TargetStrong-Buy$10.00 ➝ $11.00High
8/4/2020Cantor FitzgeraldBoost Price TargetOverweight$15.00 ➝ $20.00High
8/4/2020HC WainwrightBoost Price TargetBuy$9.00 ➝ $13.00High
8/4/2020B. RileyReiterated RatingBuy$9.00High
8/3/2020OppenheimerInitiated CoverageBuy$12.00High
8/3/2020Stifel NicolausBoost Price TargetHold ➝ Buy$8.00 ➝ $13.00High
7/30/2020Piper SandlerInitiated CoverageOverweight$12.00High
7/23/2020OppenheimerBoost Price TargetHold ➝ Outperform$6.00 ➝ $10.00High
7/23/2020Raymond JamesUpgradeOutperform ➝ Strong-BuyHigh
6/22/2020B. RileyReiterated RatingBuy$6.00High
5/26/2020HC WainwrightUpgradeNeutral ➝ Buy$9.00Medium
5/15/2020CitigroupBoost Price TargetBuy$1.60 ➝ $7.00Low
5/12/2020B. RileyUpgradeNeutral ➝ Buy$1.50 ➝ $6.00Medium
5/12/2020Roth CapitalUpgradeNeutral ➝ Buy$15.00High
5/12/2020Cantor FitzgeraldBoost Price TargetHold ➝ Overweight$5.00 ➝ $15.00High
5/12/2020SVB LeerinkUpgradeMarket Perform ➝ Outperform$2.50 ➝ $6.00High
5/12/2020Stifel NicolausUpgradeHold ➝ Buy$4.00 ➝ $8.00High
5/12/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$7.00High
5/12/2020Evercore ISIUpgradeIn-Line ➝ Outperform$15.00High
3/20/2020CitigroupLower Price TargetBuy$2.00 ➝ $1.60Low
3/18/2020B. RileyLower Price TargetNeutral$2.00 ➝ $1.50High
3/13/2020Cantor FitzgeraldUpgradeNeutral ➝ Overweight$2.00 ➝ $5.00High
3/12/2020OppenheimerUpgradeMarket Perform ➝ Buy$4.00High
1/30/2020HC WainwrightReiterated RatingHoldHigh
1/2/2020SVB LeerinkReiterated RatingMarket PerformMedium
12/20/2019HC WainwrightReiterated RatingNeutralLow
11/27/2019B. RileyReiterated RatingHold$2.00Low
11/26/2019Roth CapitalDowngradeBuy ➝ Neutral$22.00 ➝ $2.00High
11/26/2019HC WainwrightDowngradeBuy ➝ Neutral$16.00 ➝ $2.00High
11/26/2019Cantor FitzgeraldDowngradeOverweight ➝ Neutral$20.00 ➝ $2.00High
11/26/2019Raymond JamesDowngradeStrong-Buy ➝ Market PerformHigh
11/25/2019OppenheimerDowngradeOutperform ➝ HoldN/A
11/25/2019SunTrust BanksDowngradeBuy ➝ HoldN/A
11/25/2019Stifel NicolausDowngradeBuy ➝ Hold$4.00N/A
11/24/2019Evercore ISIReiterated RatingBuy$12.00High
11/6/2019HC WainwrightReiterated RatingBuyMedium
9/18/2019Cantor FitzgeraldSet Price TargetBuy$20.00Low
8/14/2019Evercore ISIReiterated RatingBuy$15.00Low
6/24/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$14.00Low
6/17/2019B. RileySet Price TargetHold$7.00Low
6/13/2019CitigroupLower Price TargetBuy$21.00 ➝ $12.00High
6/12/2019HC WainwrightReiterated RatingBuy$24.00 ➝ $12.00Low
6/11/2019B. RileySet Price TargetHold$11.00High
6/11/2019OppenheimerSet Price TargetBuy$12.00High
6/11/2019Piper Jaffray CompaniesLower Price TargetOverweight ➝ Buy$30.00 ➝ $8.00High
5/14/2019CitigroupInitiated CoverageBuy ➝ Buy$21.00 ➝ $21.00High
4/23/2019Raymond JamesSet Price TargetBuy$18.00Low
4/14/2019OppenheimerSet Price TargetBuy$18.00Medium
4/14/2019Cantor FitzgeraldSet Price TargetBuy$20.00Medium
3/1/2019Piper Jaffray CompaniesSet Price TargetBuy$30.00High
2/28/2019Cantor FitzgeraldSet Price TargetBuy$20.00High
2/22/2019SVB LeerinkInitiated CoverageOutperform$22.00High
2/21/2019SVB LeerinkReiterated RatingOutperformMedium
2/20/2019Piper Jaffray CompaniesSet Price TargetBuy$30.00Low
2/19/2019Roth CapitalReiterated RatingBuyLow
2/15/2019OppenheimerSet Price TargetBuy$18.00High
2/5/2019B. RileyInitiated CoverageHold$9.00 ➝ $9.00Medium
2/1/2019Cantor FitzgeraldReiterated RatingBuy$20.00High
12/9/2018OppenheimerSet Price TargetBuy$18.00Medium
11/23/2018Cantor FitzgeraldReiterated RatingOverweightHigh
11/19/2018HC WainwrightReiterated RatingBuyHigh
11/13/2018OppenheimerSet Price TargetBuy$18.00Low
11/7/2018OppenheimerSet Price TargetBuy$18.00Low
11/7/2018Cantor FitzgeraldSet Price TargetBuy$17.00High
10/5/2018OppenheimerSet Price TargetBuy$20.00Low
8/10/2018Piper Jaffray CompaniesBoost Price TargetOverweight$30.00Low
8/9/2018OppenheimerSet Price TargetBuy$20.00High
8/9/2018Cantor FitzgeraldReiterated RatingBuy$16.00High
6/28/2018Raymond JamesInitiated CoverageOutperform$20.00Medium
6/6/2018HC WainwrightReiterated RatingBuy$21.00 ➝ $23.00Medium
5/9/2018OppenheimerSet Price TargetBuy$20.00High
4/17/2018OppenheimerSet Price TargetBuy$20.00Low
4/13/2018HC WainwrightBoost Price TargetBuy$21.00Low
4/11/2018OppenheimerSet Price TargetBuy$18.00Medium
4/11/2018SVB LeerinkBoost Price TargetOutperform$16.00 ➝ $20.00High
3/28/2018HC WainwrightInitiated CoverageBuy$18.00Medium
3/21/2018OppenheimerReiterated RatingBuyMedium
3/16/2018SunTrust BanksReiterated RatingBuy$19.00High
3/16/2018Piper Jaffray CompaniesReiterated RatingBuy$16.00High
3/16/2018Cantor FitzgeraldReiterated RatingBuy$16.00Low
3/12/2018OppenheimerSet Price TargetBuy$18.00High
2/13/2018Evercore ISIInitiated CoverageOutperform ➝ OutperformHigh
1/25/2018Roth CapitalReiterated RatingBuy ➝ Buy$27.00High
1/24/2018HC WainwrightReiterated RatingBuy ➝ Buy$12.00 ➝ $18.00High
1/10/2018OppenheimerSet Price TargetBuy$15.00Medium
11/28/2017SVB LeerinkReiterated RatingBuy$16.00High
11/28/2017HC WainwrightReiterated RatingBuy$12.00Low
11/8/2017Cantor FitzgeraldReiterated RatingBuy$16.00N/A
10/30/2017OppenheimerSet Price TargetBuy$15.00N/A
10/27/2017Piper Jaffray CompaniesReiterated RatingBuy$12.00N/A
9/26/2017Cantor FitzgeraldReiterated RatingBuy$16.00High
9/19/2017Cantor FitzgeraldInitiated CoverageOverweight$16.00High
8/23/2017SVB LeerinkInitiated CoverageOutperform ➝ Outperform$12.00Low
8/18/2017SunTrust BanksInitiated CoverageBuy ➝ Buy$15.00High
8/11/2017Ifs SecuritiesDowngradeStrong-Buy ➝ OutperformHigh
7/25/2017Piper Jaffray CompaniesReiterated RatingPositive ➝ Overweight$12.00Low
7/20/2017CIBCReiterated RatingOutperform ➝ Outperform$8.00 ➝ $15.00Medium
7/20/2017OppenheimerBoost Price TargetOutperform$8.00 ➝ $15.00Medium
7/20/2017CitigroupReiterated RatingOutperform$8.00 ➝ $15.00Medium
7/17/2017Ifs SecuritiesReiterated RatingStrong-BuyLow
7/17/2017Piper Jaffray CompaniesSet Price TargetBuy$7.00High
7/17/2017HC WainwrightBoost Price TargetBuy$7.00 ➝ $12.00High
6/23/2017OppenheimerInitiated CoverageOutperform$8.00High
3/27/2017HC WainwrightReiterated RatingBuy$6.00 ➝ $7.00High
3/24/2017Piper Jaffray CompaniesBoost Price TargetOverweight$5.00 ➝ $6.50High
1/30/2017HC WainwrightUpgradeNeutral ➝ Buy$2.50 ➝ $6.00N/A
(Data available from 1/17/2017 forward)

News Sentiment Rating

0.68 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/21/2021
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/20/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/19/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/19/2021
  • 2 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/18/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/18/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/17/2022

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
CymaBay Therapeutics logo
CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products pipeline include Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.
Read More

Today's Range

Now: $3.15
Low: $3.02
High: $3.17

50 Day Range

MA: $3.56
Low: $3.07
High: $4.41

52 Week Range

Now: $3.15
Low: $3.02
High: $6.56

Volume

280,563 shs

Average Volume

311,380 shs

Market Capitalization

$217.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Frequently Asked Questions

What sell-side analysts currently cover shares of CymaBay Therapeutics?

The following Wall Street sell-side analysts have issued research reports on CymaBay Therapeutics in the last twelve months: B. Riley, Cantor Fitzgerald, HC Wainwright, Jonestrading, Piper Sandler, Raymond James, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for CBAY.

What is the current price target for CymaBay Therapeutics?

7 Wall Street analysts have set twelve-month price targets for CymaBay Therapeutics in the last year. Their average twelve-month price target is $10.43, suggesting a possible upside of 231.1%. Raymond James has the highest price target set, predicting CBAY will reach $14.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $7.00 for CymaBay Therapeutics in the next year.
View the latest price targets for CBAY.

What is the current consensus analyst rating for CymaBay Therapeutics?

CymaBay Therapeutics currently has 6 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CBAY will outperform the market and that investors should add to their positions of CymaBay Therapeutics.
View the latest ratings for CBAY.

How do I contact CymaBay Therapeutics' investor relations team?

CymaBay Therapeutics' physical mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The biopharmaceutical company's listed phone number is (510) 293-8800 and its investor relations email address is [email protected] The official website for CymaBay Therapeutics is www.cymabay.com.